Rani Therapeutics (RANI) Institutional Ownership $0.48 -0.01 (-2.20%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$0.49 +0.01 (+2.25%) As of 09/25/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Rani Therapeutics (NASDAQ:RANI)CurrentInstitutional OwnershipPercentage30.19%Number ofInstitutional Buyers(last 12 months)13TotalInstitutional Inflows(last 12 months)$3.21MNumber ofInstitutional Sellers(last 12 months)3TotalInstitutional Outflows(last 12 months)$106.69K Get RANI Insider Trade Alerts Want to know when executives and insiders are buying or selling Rani Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data RANI Institutional Buying and Selling by Quarter Rani Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/14/2025 Armistice Capital LLC3,151,354$1.62M0.0%N/A4.986% 7/17/2025 Janney Montgomery Scott LLC55,200$28K0.0%+102.9%0.087% 7/15/2025 Well Done LLC52,014$27K0.0%N/A0.090% 5/12/2025King Luther Capital Management Corp58,000$73K0.0%+75.8%0.101% 5/5/2025Kestra Private Wealth Services LLC139,156$175K0.0%+16.3%0.242% 4/21/2025CWA Asset Management Group LLC83,333$105K0.0%N/A0.145% 2/17/2025Two Sigma Advisers LP110,163$151K0.0%N/A0.192% 2/17/2025Two Sigma Investments LP291,381$399K0.0%N/A0.509% 2/17/2025Bridgeway Capital Management LLC56,500$77K0.0%-21.0%0.099% 2/13/2025Insigneo Advisory Services LLC47,500$65K0.0%N/A0.083% Get the Latest News and Ratings for RANI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/12/2025Takeda Pharmaceutical Co. Ltd.203,190$278K1.0%N/A0.355% 2/11/2025Virtu Financial LLC45,404$62K0.0%N/A0.079% 2/7/2025King Luther Capital Management Corp33,000$45K0.0%-59.3%0.058% 1/17/2025Janney Montgomery Scott LLC27,200$37K0.0%N/A0.047% 11/16/2024Geode Capital Management LLC172,261$372K0.0%+14.3%0.323% 11/15/2024United Services Automobile Association302,743$654K0.0%-3.0%0.567% 11/15/2024Stifel Financial Corp269,768$583K0.0%+100.4%0.505% 11/8/2024King Luther Capital Management Corp81,129$175K0.0%+44.5%0.152% 8/14/2024Marshall Wace LLP21,247$81K0.0%N/A0.042% 8/9/2024Renaissance Technologies LLC21,700$82K0.0%-69.1%0.043% 8/7/2024United Services Automobile Association312,095$1.19M0.0%-35.2%0.619% 5/10/2024Vanguard Group Inc.685,303$2.13M0.0%+2.5%1.366% 2/14/2024Alpha Square Group S LLC58,946$196K0.2%-32.2%0.118% 8/10/2023King Luther Capital Management Corp56,129$231K0.0%N/A0.113% 8/4/2023Choreo LLC19,813$82K0.0%-20.2%0.040% 5/11/2023Icon Wealth Partners LLC12,757$66K0.0%N/A0.026% 5/11/2023Alphabet Inc.448,492$2.31M0.1%-12.1%0.908% 2/8/2023Prime Capital Investment Advisors LLC33,502$198K0.0%N/A0.068% 11/18/2022TPB Wealth Advisors48,129$461K0.2%-33.0%0.098% 11/16/2022Alphabet Inc.714,471$6.85M0.3%N/A1.453% 11/3/2022Motco48,129$461K0.0%N/A0.098% 10/28/2022Lafayette Investments Inc.19,893$191K0.1%N/A0.040% 10/17/2022Canton Hathaway LLC16,200$155K0.1%+88.4%0.033% 10/14/2022Iowa State Bank18,862$181K0.1%N/A0.038% 8/8/2022Islay Capital Management LLC9,611$99K0.1%N/A0.020% 8/8/2022Crossvault Capital Management LLC14,285$148K0.1%N/A0.029% 7/29/2022Aspireon Wealth Advisors71,811$742K0.3%N/A0.146% 7/20/2022Canton Hathaway LLC8,600$89K0.0%N/A0.017% 6/15/2022Lasry Marc62,828$848K0.4%N/A0.128% 5/17/2022Lasry Marc62,828$848K0.4%N/A0.128% 5/13/2022United Services Automobile Association481,300$6.50M0.1%N/A0.979% 2/3/2022Advisor Group Holdings Inc.21,072$344K0.0%N/A0.043% 1/6/2022Canton Hathaway LLC5,000$82K0.0%-50.0%0.010% 11/16/2021Squarepoint Ops LLC50,000$891K0.0%N/A0.102% 11/15/2021Caas Capital Management LP75,000$1.34M0.0%N/A0.153% 11/10/2021Goldman Sachs Group Inc.60,649$1.08M0.0%N/A0.124% (Data available from 1/1/2016 forward) RANI Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of RANI shares? During the previous two years, 19 institutional investors and hedge funds held shares of Rani Therapeutics. The most heavily invested institutionals were Vanguard Group Inc. ($2.13M), Armistice Capital LLC ($1.62M), United Services Automobile Association ($654K), Stifel Financial Corp ($583K), Two Sigma Investments LP ($399K), Geode Capital Management LLC ($372K), and Takeda Pharmaceutical Co. Ltd. ($278K).Learn more on Rani Therapeutics' institutional investors. What percentage of Rani Therapeutics' stock is owned by institutional investors? 30.19% of Rani Therapeutics' stock is owned by institutional investors. Learn more on RANI's institutional investor holdings. Which institutional investors have been buying Rani Therapeutics' stock? Of the 15 institutional investors that purchased Rani Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Armistice Capital LLC ($3.15M), Two Sigma Investments LP ($291.38K), Takeda Pharmaceutical Co. Ltd. ($203.19K), Stifel Financial Corp ($135.15K), Two Sigma Advisers LP ($110.16K), CWA Asset Management Group LLC ($83.33K), and Janney Montgomery Scott LLC ($55.20K). How much institutional buying is happening at Rani Therapeutics? Institutional investors have bought a total of 4,265,750 shares in the last 24 months. This purchase volume represents approximately $3.21M in transactions. Which of Rani Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Rani Therapeutics stock in the last 24 months: King Luther Capital Management Corp ($48.13K), Bridgeway Capital Management LLC ($15K), and United Services Automobile Association ($9.35K). How much institutional selling is happening at Rani Therapeutics? Institutional investors have sold a total of 72,481 shares in the last 24 months. This volume of shares sold represents approximately $106.69K in transactions. Related Companies CYBN Major Shareholders LFVN Major Shareholders AVTX Major Shareholders NKTX Major Shareholders MCRB Major Shareholders ACTU Major Shareholders CRDF Major Shareholders SKYE Major Shareholders FBRX Major Shareholders KALA Major Shareholders This page (NASDAQ:RANI) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
